Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
Pharmaceutical Technology on MSN4d
Sanofi increases ownership stake partaking in pharma buyback trendJust days after taking back some of the stake held by L’Oréal, Sanofi has agreed to repurchase its own shares worth €2bn ...
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
The deal will diversify the French beauty giant’s funding sources at a time when the industry is undergoing a slowdown.
Saudi Gazette on MSN12h
Sanofi is transferring its global expertise in insulin production to Saudi ArabiaSaudi Arabia is now shifting toward localized production, a move that will significantly enhance national drug security and ...
Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...
French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...
The Indian subsidiary of French pharma major Sanofi has received marketing authorization for Rezurock (belumosudil tablets) in India.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback